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VITAMIN K ANTAGONISTS IN HEMODIALYSIS PATIENTS: 
IMPACT ON THE PLASMA LEVELS OF 
DEPHOSPHO-UNCARBOXYLATED MATRIX GLA-PROTEIN 
Background:
Matrix Gla-protein (MGP) could act as an inhibitor of vascular calcifications. Its physiological action is highly dependent of vitamin K which is necessary for the 
activation of Gla-proteins via a carboxylation process. Measurement of the inactive form of the protein, namely the desphospho-uncarboxylated matrix Gla-protein 
(dp-ucMGP), is now available (IDS, Boldon, UK). In the general population and in chronic kidney disease patients, it has been suggested that plasma 
concentrations of dp-ucMGP are higher in patients treated by vitamin K antagonist compared to non-treated. In this work, we tested if this hypothesis was also 
observed in hemodialysis patients.
Materials and methods:
Prevalent hemodialysis patients from three centers were recruited for this study. We separated patients treated, or not, by acenocoumarol. Clinical (age, gender, 
BMI, dialysis vintage, status of hypertension and diabetes, smoking status, presence of vascular antecedents) and biological variables were then compared 
between these two groups. Among biological variables, we compared classical data of the phosphorus-calcium metabolism (calcium, phosphorus, parathormone, 
25-OH vitamin D), bone biomarkers [bone-specific alkaline phosphatase (b-ALP), C-terminal telopeptide of collagen type I,  intact amino-terminal propeptide of 
type I procollagen (P1NP), tartrate-resistant acid phosphatase 5b, osteoprotegerin] and various biomarkers of interest (albumin, magnesium, C-reactive protein, 
troponin T, homocysteine, interleukin-6, TNFα, FGF-23, fetuin and dp-ucMGP). We used the Mann-Whitney test or independent samples t-test according to the 
distribution. 
Results
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Conclusion:
?In this study, we confirmed that levels of desphospho-uncarboxylated matrix Gla-protein (dp-ucMGP) were strongly influenced by vitamin K antagonist therapy 
in hemodialysis. 
?The moderate effect of vitamin K antagonist on b-ALP and P1NP deserve further studies. 
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